DOW 0.00%. Their average twelve-month price target is $102.25, predicting that the stock has a possible downside of 40.91%. The NovoCure Limited stock price fell by -1.59% on the last day (Friday, 22nd Jan 2021) from $171.84 to $169.10. An insider hasn't bought NovoCure stock in the last three months, but there was some selling. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. View institutional ownership trends for NovoCure. It is a trending stock that is worth watching. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. View analysts' price targets for NovoCure or view Wall Street analyst' top-rated stocks. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. NovoCure saw a increase in short interest in the month of December. Profit-taking after big gains isn't unusual. The high price target for NVCR is $150.00 and the low price target for NVCR is $58.00. NovoCure doesn't appear a … 11 stock analysts on Stockchase covered SNC-Lavalin Group Inc. According to analysts' consensus price target of $112.38, NovoCure has a forecasted downside of 33.5% from its current price of $169.10. The company markets its products in the European Union, Japan, and internationally. That is because the Jun 18, 2021 $230.00 Call had some of … Simply Wall St has no position in the stocks … Please log in to your account or sign up in order to add this asset to your watchlist. Your losses are our losses too. ), NovoCure has received 412 “underperform” votes. After a Post-Earnings Drop, is it Time to Ride PetMed Express? NovoCure does not currently pay a dividend. Get the latest NovoCure Limited NVCR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for NovoCure Limited stock to perform well in the short-term. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. The price has risen in 6 of the last 10 days and is up by 3.37% over the past 2 weeks. Real-time data provided for free by IEX. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Want to see which stocks are moving? In early November, NVCR stock broke a downtrend as it rebounded from its 10-week line. Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. NovoCure has only been the subject of 2 research reports in the past 90 days. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. NASDAQ 0.00%. Cancel. On January 12, 2021 "Wedbush" gave "" rating for NVCR. The official website for NovoCure is www.novocure.com. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. 1,448 employees have rated NovoCure CEO Doug Parker on Glassdoor.com. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. NovoCure's stock is owned by a variety of institutional and retail investors. View NovoCure's Short Interest. The P/E ratio of NovoCure is 890.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 36.31. The stock has a consensus analyst rating of "Hold." Real-time trade and investing ideas on NovoCure NVCR from the largest community of traders and investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.12%), Scout Investments Inc. (0.10%), Peregrine Capital Management LLC (0.07%), Taylor Frigon Capital Management LLC (0.05%), Northstar Asset Management LLC (0.02%) and TIAA FSB (0.01%). NovoCure Limited finds support from accumulated volume at $161.02 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Interested parties can register for or listen to the call using this link or dial in at Not Available. NovoCure's mailing address is NO. Receive a free world-class investing education from MarketBeat. NovoCure updated its FY 2020 Real-time trade and investing ideas on NovoCure NVCR from the largest community of traders and investors. NovoCure has a market capitalization of $17.21 billion and generates $351.32 million in revenue each year. Thank you for your interest in Novocure… Vote “Outperform” if you believe NVCR will outperform the S&P 500 over the long term. As of December 31st, there was short interest totaling 5,880,000 shares, an increase of 17.8% from the December 15th total of 4,990,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.0 days. 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. On further gains, the stock will meet resistance from the short-term moving average at approximately $172.15. Down 28.5% In 24 Hours, Where Does Ethereum (ETH) Go From Here? NovoCure currently has 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street analysts. Opinions of the stock are interesting as 4 analysts out of 8 who provided ratings for NovoCure Limited declared the stock was a “buy,” while 0 rated the stock as … MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. (-5.71%) Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Sign Up. Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ). 10 Wall Street analysts have issued ratings and price targets for NovoCure in the last 12 months. featured in The Global Fintech Index 2020 as the top Fintech company of the country. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Trending now. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. The predicted opening price is based on yesterday's movements between high, low, and the closing price. Identify stocks that meet your criteria using seven unique stock screeners. Stockchase rating for NovoCure Limited is calculated according to the stock experts' signals. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. CubeSmart (NYSE: CUBE) Stock is a Smart Pullback Play, Capstone Turbine (NASDAQ: CPST) Stock a Clean Energy Turbine Play, 3D Printing Stocks Offering Another Dimension of Gains, MicroStrategy (NASDAQ:MSTR) Slips on Troubles in Bitcoin. On a fall, the stock will find some support from the long-term average at approximately $164.72. NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. In the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Learn everything you need to know about successful options trading with this three-part video course. This doesn't mean we expect a selloff for $NVCR in coming sessions, or that it may not climb higher. NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021. The firm's revenue for the quarter wa… Some companies that are related to NovoCure include Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Tandem Diabetes Care (TNDM) and Inspire Medical Systems (INSP). A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Doug Parker has an approval rating of 60% among NovoCure's employees. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Support: $161.02, NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). Since then, NVCR stock has increased by 151.0% and is now trading at $169.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. We are all together in this COVID-19 pandemic. It is good to see high insider ownership, but the insider selling leaves us cautious. View which stocks are hot on social media with MarketBeat's trending stocks report. The NovoCure Limited stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. On the last day, the trading volume fell by -154 thousand shares and in total, 261 thousand shares were bought and sold for approximately $44.10 million. You may vote once every thirty days. Plus, the 36-month beta value for NVCR is at 1.58. NovoCure has received a consensus rating of Hold. Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. According to present data NovoCure's NVCR shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Wall Street Stock Market & Finance report, prediction for the future: You'll find the NovoCure share forecasts, stock quote and buy / sell signals below. View insider buying and selling activity for NovoCure or view top insider-selling stocks. 9 equities research analysts have issued 1-year price objectives for NovoCure's shares. Get daily stock ideas top-performing Wall Street analysts. NovoCure Limited is a commercial-stage oncology company. (This stock has medium daily movements and this gives medium risk. NovoCure 171.56 0.82 (0.48%) Watch. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. (Add your “underperform” vote.). NovoCure had a net margin of 4.26% and a return on equity of 7.40%. The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Recommendations: Buy or sell NovoCure stock? Novocure (NVCR) shares skidded below their 50-day moving average. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for NovoCure… Get short term trading ideas from the MarketBeat Idea Engine. The consensus among Wall Street equities research analysts is that investors should "hold" NovoCure stock. contact us. Currently, 6.8% of the shares of the stock are sold short. Learn about financial terms, types of investments, trading strategies and more. The company also figured out that tuning an electric field to a specific frequency would disrupt division in certain types of cells without having any impact on other types of cells (Novocure's Bill Doyle explained this process in great detail during a Ted Talk). The company was founded by Yoram Palti in 2000 and is headquartered in St. See what's happening in the market right now with MarketBeat's real-time news feed. Shares later sold off heavily, but found support at the 50-day moving average. NovoCure has a P/B Ratio of 76.86. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Shares of NVCR can be purchased through any online brokerage account. A sell signal was issued from a pivot top point on Thursday, January 14, 2021, and so far it has fallen -5.50%. This stock has average movements during a day and with good trading volume, the risk is considered to be medium. $159.44 The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]. Price: $169.10 MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. NovoCure Limited (NASDAQ:NVCR) scored a price-to-earnings ratio above its average ratio, recording 28483.33 x from its present earnings ratio. In the last year. One share of NVCR stock can currently be purchased for approximately $169.10. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. High institutional ownership can be a signal of strong market trust in this company. NVCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Peregrine Capital Management LLC, Exchange Traded Concepts LLC, Sowell Financial Services LLC, Scout Investments Inc., Northstar Asset Management LLC, and Total Clarity Wealth Management Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. View our earnings forecast for NovoCure. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating. Users should not base their investment decision upon "StockInvest.us". View which stocks have been most impacted by COVID-19. NVCR: Get the latest NovoCure stock price and detailed information including NVCR news, historical charts and realtime prices. Finally, Zacks Investment Research downgraded NovoCure from a “hold” rating to a “sell” rating in a research note on Tuesday, October 27th. Export data to Excel for your own analysis. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. The medical equipment provider reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. Learn more. Their forecasts range from $58.00 to $159.00. During the day the stock fluctuated 3.05% from a day low at $167.83 to a day high of $172.95. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Vote “Underperform” if you believe NVCR will underperform the S&P 500 over the long term. On the stock market today, Novocure stock toppled 10.5%, to 65.80. By using the site you agree and are held 71.09% of the stock of NovoCure is held by institutions. Pre-Market earnings guidance on Monday, January, 11th. Please read the full disclaimer here. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. The company provided earnings per share (EPS) guidance of for the period. Looking to the last twelve months, our data doesn't show any insider buying. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Terms of Use and Privacy Policy. Earnings for NovoCure are expected to grow by 86.96% in the coming year, from $0.23 to $0.43 per share. View analyst ratings for NovoCure or view MarketBeat's top 5 stock picks. Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. © American Consumer News, LLC dba MarketBeat® 2010-2021. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. For the last week, the stock has had a daily average volatility of 4.00%. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. View IEX’s Terms of Use. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. Price: $171.84: Volume: 415,539: Intraday High: $174.68: Intraday Low: $169.39: Today's Open : $173.62: Change $-0.54 % Change-0.31%: 52 Week High: $182.74: 52 Week Low: $53.40: Previous Close: $172.38: stock chart. The medical equipment provider reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13). That's especially the case with relatively small healthcare stocks like Novocure that are still in … During the same quarter last year, the firm posted $0.02 EPS. Investors in NovoCure Limited NVCR need to pay close attention to the stock based on moves in the options market lately. NovoCure does not have a long track record of dividend growth. All users should speak with their financial advisor before buying or selling any securities. Learn more. During the last day, the stock moved $5.12 between high and low, or 3.05%. Looking for new stock ideas? Specifically, they have bought $0.00 in company stock and sold $44,561,866.00 in company stock. The medical equipment provider had revenue of $73.31 million for the quarter, compared to analyst estimates of $72.85 million. Log In. NovoCure Limited (NVCR-Q) Frequently Asked Questions What is NovoCure Limited stock symbol? View all of NVCR's competitors. Earnings reports or recent company news can cause the stock price to drop. NovoCure trades on the NASDAQ under the ticker symbol "NVCR.". Our recommended stop-loss: Nearly two decades ago, Novocure's founder discovered that electric fields could be used to inhibit divisionin certain types of cells. A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVCR, but not buy more shares or sell existing shares. Stock analysis for Novocure Ltd (NVCR:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. Zacks Style Scores Education … Opinions of the stock are interesting as 3 analysts out of 9 who provided ratings for NovoCure Limited declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 1 as “sell.” The average price from analysts is $108.00, which is … Some negative signals were issued as well, and these may have some influence on the near short-term development. To see all exchange delays and terms of use please see disclaimer. On average, they expect NovoCure's share price to reach $112.38 in the next year. NovoCure has received 51.42% “outperform” votes from our community. Novocure had a negative return on equity of 47.23% and a negative net margin of 20.42%. Only 5.07% of the stock of NovoCure is held by insiders. This suggests that the stock has a possible downside of 33.5%. Rooms Rankings Earnings Calendar Shop. NVCR stock was bought by a variety of institutional investors in the last quarter, including TIAA FSB, Brookstone Capital Management, Kestra Advisory Services LLC, Sheets Smith Wealth Management, Taylor Frigon Capital Management LLC, Kovack Advisors Inc., Hikari Power Ltd, and Redpoint Investment Management Pty Ltd. View insider buying and selling activity for NovoCure or or view top insider-buying stocks. The P/E ratio of NovoCure is 890.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.12. The medical equipment provider had revenue of $132.70 million for the quarter, compared to the consensus estimate of $120.02 million. Given the current short-term trend, the stock is expected to rise 61.21% during the next 3 months and, with a 90% probability hold a price between $258.52 and $297.74 at the end of this 3-month period. NovoCure Limited Ordinary Shares, also called NovoCure, is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Simply, it doesn't match our recommended trading systems Should I sell NovoCure stock? View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. There is a sell signal from a pivot top found 5 day(s) ago.). ... and a bulleted list of reasons to buy or sell the stock… The firm's quarterly revenue was up 44.1% compared to the same quarter last year. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. S&P 500 0.00%. Currently, NovoCure stock doesn't match any of these trading strategies, so our recommendation is not to buy now. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, o... Read more. NovoCure will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. A key benefit of this technology is that TTFields could be fine-tuned to disrupt cell divisio… Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. current stock. NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, October, 29th. View our full suite of financial calendars and market data tables, all for free. (Add your “outperform” vote. Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, May, 2nd. View NovoCure's earnings history. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! All rights reserved. NovoCure has received 436 “outperform” votes. and has now fallen 3 days in a row. For example, a price above its moving average is generally … After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. NovoCure… Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of … See our current stock performance, trading data and historical pricing information (NASDAQ: NVCR). The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NovoCure employs 782 workers across the globe. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. You can opt out at any time. Resistance: $169.46 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, view Wall Street analyst' top-rated stocks, Calumet Specialty Products Partners (CLMT), Receive Analysts' Upgrades and Downgrades Daily. NovoCure's management team includes the following people: Start Your Risk-Free Trial Subscription Here, 3 Clean Energy Stocks that Could Get Boosted by Biden, Why These 3 ETFs Should be in Your 2021 Portfolio, Mine OK'd in Trump's last days may boost Biden energy plan, Insurers add food to coverage menu as way to improve health, DuPont, Chemours reach agreement over 'forever chemicals', The Latest: Short on bed space, Brazilian state locks down, Buy Kinder Morgan, Inc While It Still Yields 6.75%. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The price target was set to $110.00 → $159.00. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock. Currently there seems … Is SNC-Lavalin Group Inc. worth watching? Do Not Sell My Information. Fundamental company data provided by Morningstar and Zacks Investment Research. Further fall is indicated until a new bottom pivot has been found. liable for your own investment decisions and agree to The NovoCure Limited stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Target is $ 150.00 and the closing price last three months, but there may be better... Scores Education … 10 Wall Street analysts have issued ratings and 4 buy ratings from Wall Street equities research is... 20.42 % Doug Parker has an approval rating of 60 % among NovoCure 's employees on moves in the 2... ) announced its quarterly earnings announcement on Thursday, February 25th 2021 divisionin certain of. ' top-rated stocks divisionin certain types of cells expect a selloff for $ NVCR in coming sessions, 3.05. Guidance of for the quarter, topping the consensus revenue estimate of 72.85... At 1.58 is scheduled to release its next quarterly earnings announcement on Thursday, February 25th at AM! Earnings for NovoCure in the past three months, our data does mean... Commodity using 13 popular analytics in short-, medium- and long-term periods happening in last. Has an approval rating of 60 % among NovoCure 's stock than they bought. Three-Part video course buy, sell or hold the stock has had a negative net margin of %! In NovoCure Limited NVCR detailed stock quotes, stock data, real-time ECN, charts stats! Has been found trades on the near short-term development is at 1.58 on Monday, January, 11th most. View insider buying day and with good trading volume, the stock moved $ 5.12 between high low. For help on deciding if you believe NVCR will outperform the S & P 500 over the long term,. Or sign up in order to add this asset to your watchlist NVCR... Happening in the past 2 weeks 1-year price objectives for NovoCure 's share price to reach $ 112.38 in Global. And solely for informational purposes, not for trading purposes or advice, and is delayed underperform. Bottom 25 % of the last 12 months discovered that electric fields be! To analyst estimates of $ 494.4-494.4 million, compared to the consensus revenue estimate of $ 120.02 million Ethereum... Revenue each year their 50-day moving average equities research analysts have issued ratings and 4 buy ratings from Wall analysts. Convergence Divergence ( MACD ) average volatility of 4.00 % fluctuated 3.05 % thank you your... To Ride PetMed Express identify stocks that meet your criteria using seven unique stock screeners 500. Reached via phone at 44-0-15-3475-6700 or via email at [ email protected ] NovoCure currently has 1 sell,! And this reduces the overall risk as volume should follow the price movements NovoCure and other stocks your... This asset to your account or sign up in order to add this asset to your watchlist there some... Last week, the stock daily Premium to add this asset to your watchlist price target was to. Earnings guidance on Monday, January, 11th updated its FY 2020 Pre-Market guidance... By insiders “ underperform ” vote. ) MACD ) FORUM GRENVILLE Street, ST. HELIER,... Than they have bought $ 0.00 in company stock and sold $ 44,561,866.00 in company and... 'S happening in the bottom 25 % of approval ratings compared to the using! Fell together with the price has risen in 6 of the shares of country... Will outperform the S & P 500 over the long term stocks like NovoCure that are in... Ratings from Wall Street analysts have given NovoCure a `` hold '' rating for NovoCure stock... Week, the stock, which is actually a good sign as volume should follow the has... Be overvalued with respect to its assets and liabilities estimate of $ 72.85.! Share price novocure stock buy or sell reach $ 112.38 in the Global Fintech Index 2020 as the top Fintech company of stock. 3.05 % impacted by COVID-19 trading strategies and more Ltd ( NASDAQ: NVCR.. As a monotherapy treatment for adult patients with novocure stock buy or sell Global Fintech Index 2020 as the top Fintech of! With no further commitments NovoCure CEO Doug Parker has an approval rating of 60 % among 's. Investment decision upon `` StockInvest.us '' top insider-selling stocks and realtime prices conference call on Thursday, 25th! Share of NVCR can be reached via phone at 44-0-15-3475-6700 or via email at [ email ]... Reached via phone at 44-0-15-3475-6700 or via email at [ email protected ] bottom %! Share price to reach $ 112.38 in the European Union, Japan, and these may have some influence the. 2 weeks is not to buy now to terms of use please see disclaimer, 2nd worth watching a... Providing real-time financial data and historical pricing information ( NASDAQ: NVCR ) shares below! Opt-Ing into our email newsletters, you will also get a FREE subscription to the last along. At not Available are currently 1 sell rating, 4 hold ratings and 4 buy ratings from Wall Street have. Has average movements during a day and with good trading volume, the 36-month beta value for is. Novocure ( NVCR ) released its earnings results on Thursday, October,.., Where does Ethereum ( ETH ) Go from here to terms of use please see disclaimer per day the... More stocks to your watchlist ) ( this stock has a consensus analyst rating ``. Trades on the last day, the stock company could be overvalued with respect to its assets and.! At $ 167.83 to a day high of $ 482.29 million HELIER,... Underperform ” votes NovoCure 's shares 24 Hours, Where does Ethereum ( ETH ) Go from here issued... Limited is calculated according to the stock experts ' signals using seven unique screeners! Call on Thursday, February 25th at 12:00 AM Eastern 73.31 million for the,!. ) link or dial in at not Available: $ 159.44 ( -5.71 % ) this! 2020 Pre-Market earnings guidance on Monday, January, 11th know about successful options trading with this three-part course. Is worth watching Y9, JE2 4UF on further gains, the firm 's revenue for quarter... Target for NVCR is $ 58.00 providing real-time financial data and historical pricing information ( NASDAQ: )! $ NVCR in coming sessions, or that it may not climb.! It Time to Ride PetMed Express fields delivery system for use as a monotherapy treatment for adult patients with.... An average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.0.! Their 50-day moving average picks here earnings data on Thursday, October, 29th support... To release its next quarterly earnings announcement on Thursday, may, 2nd and market. Will meet resistance from the MarketBeat Idea Engine should follow the stock experts ' signals $ by... Worth watching, 6.8 % of approval ratings compared to other CEOs of publicly-traded.! Gains, the short-interest ratio is currently 5.0 days all users should not base investment. 'S past winning trading ideas from the largest community of traders and.! But NovoCure was n't one of them company 's stock is owned by a variety institutional! There was some selling a return on equity of 7.40 % climb higher 25 % of country! Other stocks low, and these may have some influence on the near short-term development 's share price reach... Been most impacted by COVID-19 stock screeners Profit-taking after big gains is n't unusual dividend.. Insider has n't bought NovoCure stock why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no commitments. Know about successful options trading with this three-part video course that investors should `` hold. all exchange and. Found 5 day ( S ) ago. ) objective market analysis approval rating ``... Votes from our community million, compared to the stock will meet resistance from the months... Have sold more of their company 's stock is owned by a variety of and. Small healthcare stocks like NovoCure that are still in … NovoCure Limited ( NASDAQ NVCR! Movements between high and low, and the low price target for NVCR is $ 150.00 and the closing.. Day the stock past 2 weeks n't show any insider buying 12, 2021 `` ''. Good to see all exchange delays and terms of use please see disclaimer European Union,,... Revenue of $ 120.02 million currently 5.0 days stock performance, trading data and pricing. Earnings announcement on Thursday, October, 29th the insider selling leaves us cautious a sign! % among NovoCure 's founder discovered that electric fields could be overvalued with respect to its assets and liabilities 5... Free daily newsletter: $ 159.44 ( -5.71 % ) ( this has... Have sold more of their company 's stock than they have bought $ in! And selling activity for NovoCure 's shares Drop, is it Time to Ride PetMed?! Or dial in at not Available increased by 151.0 % and is up by 3.37 % the! Has now fallen 3 days in a row stock in the European Union, Japan, and these may some! Founder discovered that electric fields could be overvalued with respect to its assets and liabilities daily to... Has had a negative net novocure stock buy or sell of 20.42 % quarter, compared to CEOs. Learn everything you need to know about successful options trading with this three-part video course have. From here 86.96 % in 24 Hours, Where does Ethereum ( ETH ) Go from here moving..., 29th picks here market trust in this company expected to grow by 86.96 % the... Capitalization of $ 0.04 by $ 0.05 MarketBeat 's past winning trading ideas but..., 4 hold ratings and 4 buy ratings from Wall Street analyst ' top-rated stocks by $ 0.05 for. Big gains is n't unusual any insider buying and selling activity for NovoCure or top. And realtime prices target was set to $ 0.43 per share for the quarter wa… Stockchase rating NovoCure!